26th Annual Controversies, Problems and Techniques in Surgery

Activity Name
26th Annual Controversies, Problems and Techniques in Surgery

Activity Type
CME Meeting

On-site registration will be available
 
Activity Directors
Robert E. Michler
Surgeon-in-Chief
Samuel I. Belkin Chair
Professor and Chairman,
Department of Surgery and
Department of Cardiothoracic Surgery
Montefiore Medical Center/Albert Einstein College
New York

Steven K. Libutti
Director, MMC-Einstein Center for Cancer Care
Associate Director, Albert Einstein College of Med
Professor and Vice-Chairman, Dept. of Surgery
Montefiore Medical Center/Albert Einstein College

Ronald N. Kaleya
Professor of Clinical Surgery, Dept. of Surgery
Residency Program Director
Montefiore Medical Center/Albert Einstein College

 
Activity Specialties
SURGEONS

 
Activity Dates and Expiration
Begins: December 10, 2009
Ends: December 12, 2009
Time:07:00 AM
Location: The Sheraton New York Hotel and Towers 811 Seventh Avenue New York, New York
Phone: 718-920-6674 ext. 239
URL: http://www.surgerysymposium.org
Email:  jsaalman@montefiore.org
 
Intended Audience
This conference has been designed to assist practicing general and oncology surgeons and other surgical health professionals in evaluating standards of care and new techniques and interventions for surgical conditions of colorectal, breast,and endocrine cancer and other topics in surgery.
Activity Goals and Needs
The goal of this activity is to help the practicing surgeon analyze new therapies/techniques/diagnostic interventions in the context of current standards of care as they relate to colorectal, breast and endocrine diseases and other aspects of general surgery.
Educational Objectives
At the conclusion of this conference, participants should be able to:

1. Summarize and describe the nature of multidisciplinary therapy for rectal cancer and be able to develop a treatment plan after consideration of findings following preoperative chemo radiation.

2. Define the time from preoperative chemoradiation therapy to surgery (for rectal cancer) and alternatives to surgical intervention for advanced or recurrent colorectal cancer.

3. Diagnose anal intra-epidermal neoplasia, carcinoma-in-situ of the anus and anal condylomata and understand the relative efficacies of the therapies involved in the treatment of these diseases.

4. Discuss the outcomes and controversies with respect to local and minimally invasive therapy of rectal cancer.

5. Analyze the controversies in the management of breast core biopsy pathology results, surgical margins for breast cancer and nipple discharge.

6. Evaluate the indications and outcomes for conservative management of breast cancer and risk reducing breast surgery.

7. Understand the recent advances in minimally invasive surgery for appendicitis, colon cancer, biliary disease and thyroid/parathyroid disease.

8. Describe the newest paradigms in the management of thyroid cancer, adrenal tumors and pancreatic neuroendocrine tumors.

9. Appreciate the future therapies for breast, rectal and endocrine diseases.
Activity Credits and Accreditation
Activity Credits: 19

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this educational activity for a maximum of 19 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Faculty Disclosure / COI Statement
CONFLICT OF INTEREST STATEMENT
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.